259860-08-7

Usage

Uses

Used in Pharmaceutical Industry:
6-Bromo-5-fluoroindole is used as a key intermediate in the synthesis of potential drug candidates for the treatment of various diseases. Its unique structural features allow for the development of novel therapeutic agents with improved efficacy and selectivity.
Used in Medicinal Chemistry:
6-Bromo-5-fluoroindole is employed as a versatile building block in medicinal chemistry, enabling the design and synthesis of new compounds with potential biological activities. Its presence in the molecular structure can influence the pharmacokinetic and pharmacodynamic properties of the resulting compounds, contributing to their therapeutic potential.
Used in Drug Discovery:
6-Bromo-5-fluoroindole is utilized as a starting material in drug discovery processes, facilitating the identification and optimization of new chemical entities with potential therapeutic applications. Its diverse applications in this field highlight its importance in the development of innovative treatments for various medical conditions.

InChI:InChI=1/C8H5BrFN/c9-6-4-8-5(1-2-11-8)3-7(6)10/h1-4,11H

Upstream product

• 224185-19-7 3-bromo-4-fluoro-6-methylnitrobenzene 
• 259860-00-9 2-fluoro-4-methyl-5-nitro-phenylamine 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 1034894-73-9 [2-(4-bromo-5-fluoro-2-nitro-phenyl)-vinyl]-dimethyl-amine 

Downstream Products

• 1211593-30-4 6-bromo-5-fluoro-1H-indole-3-carbonitrile 
• 1403898-91-8 5-fluoro-6-phenyl-1H-indole 
• 1403898-90-7 5-fluoro-6-phenyl-2,3-dihydro-1H-indole 

Relevant academic research and scientific papers

REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS

The present disclosure provides compounds of Formula IA and Formula IB and their pharmaceutical compositions as selective agonists of REV-ERB-α: where R1, R2, R3, R4, R5, RX1, RX2, nA, nB, X, Y, and Z are described herein. The compounds are useful in various methods and uses, such as in the treatment of diseases including hyperglycemia, dyslipidemia, atherosclerosis, and autoimmune and inflammatory disorders or diseases, and as cancer therapeutics, such as for the treatment of glioblastoma, hepatocellular carcinoma, and colorectal cancer, and for immune-oncology purposes.

INHIBITORS OF CYCLIN DEPENDNT KINASE 7 (CDK7)

The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

SUBSTITUTED QUINOXALINE DERIVATIVES

The present invention relates to substituted quinoxaline derivatives. These compounds are useful for the prevention and/or treatment of several medical conditions including hyperproliferative disorders and diseases.

3-BENZOFURANYL-4-INDOLYL MALEIMIDES AS POTENT GSK3 INHIBITORS FOR NEUROGENERATIVE DISORDERS

Compounds of formula (I): and pharmaceutically acceptable salts, esters and solvates thereof, where variables are defined in the specification, useful generally as inhibitors of protein kinases and particularly useful for inhibition of GSK-3. Pharmaceutically compositions and medicaments containing a compound of the invention are provided. The invention provides methods of treatment of protein kinase-related disease, disorders or conditions. The invention provides methods of treatment of GSK-3-related diseases, disorders or conditions. More specifically, methods of treatment of bipolar disorder, including mania, schizophrenia, stroke, epilepsy, motor neuron disease, cranial or spinal trauma, neurodegenerative disorders, including multiple sclerosis (MS), Alzheimer's disease, Fragile X syndrome, autism, Huntington's disease, Parkinson's

Substituted indoles as alpha-1 agonists

This invention relates to compounds which are alpha-1 receptor agonists, preferably alpha-1A/L receptor agonists, and which are represented by Formula I: wherein m, A, X, Y, R1, R2, R3, R4 and R5 are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and methods of preparation thereof.

Indoline derivatives as 5-HT2B and or 5-HTC receptor ligands

For use in therapy a chemical compound of formula (I), wherein R1to R3are independently selected from hydrogen and alkyl; R4to R7are independently selected from hydrogen, halogen, hydroxy, alkyl, aryl, heterocyclyl, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfoxyl, alkylsulfonyl, arylsulfoxyl, arylsulfonyl, amino, monoalkylamino, dialkylamino, nitro, cyano, carboxaldehyde, alkylcarbonyl, arylcarbonyl, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, alkoxycarbonylamino, aminocarbonyloxy, monoalkylaminocarbonyloxy, dialkylaminocarbonyloxy, monoalkylaminocarbonylamino and dialkylaminocarbonylamino, wherein at least one of R4to R7is a substituent group other than hydrogen, and pharmaceutically acceptable salts and prodrugs thereof, particularly for the treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea, and especially for the treatment of obesity; chemical compounds of formula (I) other than compounds wherein R7is hydroxy.